Ensuring ample cash reserves to support development of its cancer and inflammatory drug pipeline, Micromet Inc. gained access to up to $25 million through a committed equity financing facility.
[News Source]
[News Source]
Blogosphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg


